查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1258889

到 2028 年的干細胞療法市場預測——按產品類型、療法、技術、應用、最終用戶和地區進行的全球分析

Stem Cell Therapy Market Forecasts to 2028 - Global Analysis By Product, Therapy Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2022 年全球幹細胞治療市場將達到 2.57 億美元，預計到 2028 年將達到 7.224 億美元，預計將以 18.8 的複合年增長率增長%。

人類和動物都有乾細胞，這是體內最有價值的細胞。 幹細胞是能夠增殖並長成體內所有類型細胞的細胞，可用於外科手術和醫學。 有兩種類型的干細胞：成體幹細胞和胚胎幹細胞。 胚胎幹細胞是源自人類胚胎的干細胞 (ESC)。 這種細胞是多能的，可以發育成體內幾乎任何類型的細胞。 幹細胞療法也被稱為再生醫學和中樞療法。 再生醫學具有再生細胞和替換受損或死亡細胞的能力。

根據國際癌症研究機構 2020 年的估計，五分之一的人會在生命中的某個階段患上癌症，八分之一的男性和十一分之一的女性會死亡。它是

市場動態：

驅動程序：

慢性病患病率和發病率上升

慢性病影響著全世界大多數人。 世界上有三分之一的成年人患有慢性病。 許多人的健康和生活質量受到慢性病的負面影響。 癌症、肌肉骨骼和神經系統問題、慢性損傷、心血管和胃腸道疾病以及癌症都會導致住院、長期殘疾、生活質量差和死亡。還有 間充質乾細胞滲透並整合到各種器官中，用於治療肺、脊髓、自身免疫、肝臟、骨骼和軟骨疾病，以及多器官疾病。 使用乾細胞治療炎症性疾病、免疫系統疾病和退行性組織疾病是一種成功的途徑。

抑制：

關於胚胎幹細胞的倫理問題

對胚胎幹細胞 (ESC) 治療潛力的調查與許多與人類胚胎破壞相關的倫理問題有關。 未來，由於缺乏明確的聯邦政策來定義胚胎幹細胞研究和治療開發將支持什麼，可能會在一定程度上限制市場擴張。 此外，該領域法律的複雜性要求政府制定指導方針，以幫助研究人員、科學家和製藥公司開發胚胎幹細胞療法並促進其商業化。

機會

幹細胞研究的資助潛力

近年來，由於心血管、神經和自身免疫性疾病患者需要新的治療方法，用於乾細胞研究的資金有所增加。 2018年NIH對乾細胞研究的資助創下新高，同比增長超過5%。 隨著計劃在 2021 年增加的貸款活動，這一趨勢預計將繼續下去。 例如，2021 年 9 月，加州再生醫學研究所授予斯坦福研究院 3100 萬美元，用於啟動干細胞治療心力衰竭、中風和脊髓腫瘤的首次人體研究。

威脅

昂貴的醫療費用

細胞療法的高成本限制了市場擴張。 隨著人們尋求最新的治療方法，細胞療法已發展成為一種突出的治療方法。 儘管需求大幅增加，但細胞療法仍然太昂貴而無法嘗試。 視情況而定，一次簡單的關節注射費用可能高達 1,000 美元，而更高級的手術費用可能高達 100,000 美元。 到 2020 年，美國干細胞療法的平均費用預計將在每位患者 4,000 至 8,000 美元之間。 因此，高昂的治療費用限制了乾細胞治療市場的擴張。

COVID-19 的影響：

COVID-19 大流行對乾細胞治療行業影響不大。 由於許多研究機構和政府機構專注於尋找快速有效的解決方案來治療和預防像 COVID-19.rice field 這樣的危險疾病，市場上出現了很多活動。 事實上，大流行已成為在全球範圍內啟動再生醫學臨床試驗所需的動力。 幾項臨床試驗已經證實，MSC 療法可能是 COVID-19 患者的一種可行的治療選擇，尤其是那些患有急性呼吸窘迫綜合徵的患者。

預計在預測期內自體片段將是最大的

由於自體幹細胞利用率的提高和各種干細胞產品的可用性，自體幹細胞領域有望實現利潤豐厚的增長。 細胞技術的最新進展導致對許多患病細胞及其新陳代謝的分子理解，增加了對治療性幹細胞療法的需求。 可負擔性、提高患者存活率、無需確定 HLA 匹配的供體以及移植物抗宿主病風險降低有望推動該領域的擴展。

預計在預測期內，電池採集部分的複合年增長率最高。

在預測期內，電池採集行業預計將實現最快的複合年增長率。 胚胎幹細胞的發現為開發針對各種疾病的創新療法鋪平了道路。 這些細胞具有多能性，可用於在體內分化成許多不同的細胞類型。 然而，直接從胚胎中收集細胞在倫理上存在問題。 因此研究人員找到了另一種選擇：iPS 細胞。 細胞採集進一步細分為骨髓採集、臍帶血採集和單採。

市場份額最高的地區

由於強大的生物技術產業、主要參與者的主導地位、研發的巨大努力以及個性化醫療的推廣，預計北美在預測期內將佔據最大的市場份額。 此外，該領域的興起可歸因於政府為促進乾細胞療法而採取的更多舉措。 例如，2020 年 3 月，加拿大政府投資約 700 萬美元用於再生醫學和乾細胞研究。 這將通過資助九項跨境計劃和四項臨床試驗來支持該國在再生醫學領域的擴張。

複合年增長率最高的地區：

由於基於乾細胞的藥物的開發、政府對製造再生藥物的努力、多個乾細胞庫的建立以及基因工程和生物醫學研究的臨床研究增加，亞太地區正在經歷顯著增長。,預計在預測期內表現出最高的複合年增長率。 例如，印度政府計劃到 2022 年 2 月在 40 家頂級醫學研究和教育機構擁有最先進的干細胞研究設施。

市場主要參與者

幹細胞治療市場的主要參與者包括：CORESTEM、Regrow Biosciences Pvt Ltd.、Takeda Pharmaceutical Company Limited、Medipost Co., Ltd.、Orthofix Holdings, Inc.、Smith & Nephew plc、Novadip Biosciences、Fuji Film Holding Co., Ltd.、Astellas Pharma Inc.、Allele Biotechnology and Pharmaceuticals, Inc.、NuVasive, Inc.、Mesoblast Co., Ltd.、Anterogen 和 AlloSource。

主要發展：

2022 年 7 月，CORESTEM（韓國）繼續招募參與者參加 NeuroNata-R 的 3 期臨床試驗。 該療法已在韓國獲得有條件批准用於治療 ALS 患者。

這份報告提供了什麼

  • 區域級、國家級細分市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場驅動因素（市場趨勢、制約因素、機遇、威脅、挑戰、投資機會、建議等）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局和趨勢
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 供應鏈趨勢反映了最新的技術進步。

提供免費定制

購買此報告的客戶將免費獲得以下定制之一。

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶要求提供主要國家/地區的市場估算、預測和復合年增長率（注意：基於可行性檢查。）
  • 競爭基準
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究信息來源
    • 二手研究資源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球幹細胞治療市場：按產品分類

  • 人類胚胎幹細胞 (HESC)
  • 非常小的類胚胎幹細胞
  • 成體幹細胞 (ASC)
    • 上皮/皮膚
    • 造血
    • 神經
    • 間充質系統
    • 其他成體幹細胞 (ASC)
  • 誘導多能幹細胞 (iPSC)

第 6 章全球幹細胞療法市場：按治療類型分類

  • 同種異體
  • 首頁

第 7 章全球幹細胞治療市場：按技術分類

  • 擴張和亞文化
  • 細胞生產
    • 細胞培養
    • 體外受精
    • 隔離
    • 治療性克隆
  • 冷凍保存
  • 獲取單元格
    • 單採術
    • 骨髓採集
    • 臍帶血

第 8 章全球幹細胞治療市場：按應用

  • 藥物發現和開發

再生醫學

    • 糖尿病
    • 尿失禁
    • 腫瘤學
    • 心血管和心肌梗塞
    • 神經學
    • 受傷
    • 骨科
    • 肝損傷
    • 血液學
    • 其他再生醫學

第 9 章全球幹細胞治療市場：按最終用戶分類

  • 學術和研究機構
  • 製藥和生物技術公司
  • 醫院和細胞庫

第 10 章全球幹細胞治療市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第11章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • CORESTEM
  • Regrow Biosciences Pvt Ltd.
  • Takeda Pharmaceutical Company Limited
  • MEDIPOST Co., Ltd.
  • Orthofix Holdings, Inc.
  • Smith & Nephew plc
  • Novadip Biosciences
  • Fujifilm Holding Corporation
  • Astellas Pharma Inc.
  • Allele Biotechnology and Pharmaceuticals, Inc.
  • NuVasive, Inc.
  • Mesoblast Ltd.
  • Anterogen.Co., Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • AlloSource
Product Code: SMRC22769

According to Stratistics MRC, the Global Stem Cell Therapy Market is accounted for $257 million in 2022 and is expected to reach $722.4 million by 2028 growing at a CAGR of 18.8% during the forecast period. Humans and animals both have stem cells, which are the most valuable cells in the body. Stem cells are cells that have the ability to proliferate and grow into practically any cell type in the body, and they are used in surgery and medicine. There are two types of stem cells: adult stem cells and embryonic stem cells. Embryonic stem cells are stem cells derived from human embryos (ESCs). They are pluripotent, which means they can develop into almost any type of cell in the body. Stem cell therapy is also known as regenerative medicine or centrepiece therapy. Regenerative medications have the ability to regenerate cells and replace those that have been damaged or perished.

According to estimates from the International Agency for Research on Cancer 2020, 1 in 5 people will develop cancer at some point in their lives, and 1 in 8 men and 1 in 11 women will pass away.

Market Dynamics:

Driver:

The rise in prevalence and incidence of chronic diseases

Chronic illnesses affect the vast majority of individuals worldwide. One in in three adults globally suffers from a chronic illness. Many people's health and quality of life have been negatively influenced by chronic diseases. Cancer, musculoskeletal and neurological problems, chronic injuries, cardiovascular and gastrointestinal conditions, and cancer can all lead to hospitalisation, long-term incapacity, a reduction in quality of life, and even death. Mesenchymal stem cells penetrate and integrate into various organs, treating lung, spinal cord, autoimmune illnesses, liver, bone, and cartilage diseases, and treating multiple organ damage. The use of stem cells in the treatment of inflammatory, immune system, and degenerative tissue diseases is a successful method.

Restraint:

Ethical concerns related to embryonic stem cells

Research into the therapeutic potential of embryonic stem cells (ESC) are linked to a number of ethical concerns related to the destruction of human embryos. In the future, a lack of clear federal policies defining what can be supported in embryo-based stem cell research or therapy development may limit market expansion to some extent. Furthermore, the complexities of legislation in this sector necessitate government guidelines that can assist researchers, scientists, and pharmaceutical companies in developing ESC therapy and facilitating its commercialization.

Opportunity:

Availability of funding for stem cell research

Stem cell research funding has increased in recent years, owing to the need for novel therapeutic approaches in patients with cardiovascular, neurological, and autoimmune illnesses. The NIH funding for stem cell research reached a new high in 2018, with a year-on-year increase of more than 5%. This trend is projected to continue with the increase in financing efforts planned in 2021. For example, in September 2021, the California Institute for Regenerative Medicine awarded Stanford Research a USD 31 million funding to launch first-in-human studies of stem cells in the treatment of heart failure, stroke, and spinal cord tumours.

Threat:

High cost of treatment

The high cost of cell therapy has limited market expansion. Cell therapies have developed as a prominent treatment option as people seek out the most recent therapy options. Despite the significant increase in demand, cell therapies remain too expensive to try. Simple joint injections can cost up to $1,000 depending on the situation, whereas more sophisticated surgeries might cost up to $100,000. The average cost of stem cell therapy in the United States is expected to be between $4,000 and $8,000 per patient in 2020. As a result, the high cost of treatment limits the expansion of the stem cell therapy market.

COVID-19 Impact:

The COVID-19 pandemic had little effect on the stem cell therapy industry. The market saw a lot of activity because many research and government entities were focused on finding rapid and effective solutions to cure and prevent dangerous disorders like COVID-19. In fact, the pandemic provided the impetus needed to launch worldwide regenerative medicine clinical trials. Several clinical investigations have confirmed that MSC therapy could be a viable treatment option for COVID-19 patients, particularly those with acute respiratory distress syndrome.

The autologous segment is expected to be the largest during the forecast period

The autologous segment is estimated to have a lucrative growth, because of the increased usage of autologous stem cells and the availability of a variety of stem cell products. Recent advances in cellular technology have contributed to a better understanding of numerous disease cells and their metabolism at the molecular level, pushing the demand for stem cell therapies for treatment. Affordability, better patient survival rate, no need to identify an HLA-matched donor, and minimal risk of graft-versus-host disease are all expected to drive the expansion of this segment.

The cell acquisition segment is expected to have the highest CAGR during the forecast period

The cell acquisition segment is anticipated to witness the fastest CAGR growth during the forecast period. The discovery of embryonic stem cells has paved the path for the development of innovative treatments for a variety of ailments. These cells are pluripotent, which means they can be utilised to differentiate many different types of cells in the body. Obtaining embryonic cells directly from the embryo, on the other hand, has created ethical difficulties. As a result, researchers discovered an alternative-iPS cells. Cell acquisition is further subdivided into bone marrow harvest, umbilical blood cord harvest, and apheresis.

Region with highest share:

North America is projected to hold the largest market share during the forecast period, because of the robust biotechnology industry, the domination of major key firms, considerable R&D efforts, and the promotion of individualised medications. Furthermore, this sector's rise can be attributable to a growing government initiative to promote stem cell therapy. For example, in March 2020, the Canadian government invested around USD 7 million towards regenerative medicine and stem cell research. It will support the country's expansion in the regenerative medicine sector by funding nine transnational initiatives and four clinical trials.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, because of the development of stem cell-based medicines, government initiatives for producing regenerative drugs, the establishment of multiple stem cell banks, and the region's growing clinical studies for genetic engineering and biomedical research. For example, the government of India has established cutting-edge stem cell research facilities in 40 top health research and educational institutes by February 2022.

Key players in the market:

Some of the key players profiled in the Stem Cell Therapy Market include: CORESTEM, Regrow Biosciences Pvt Ltd., Takeda Pharmaceutical Company Limited, MEDIPOST Co., Ltd., Orthofix Holdings, Inc., Smith & Nephew plc, Novadip Biosciences, Fujifilm Holding Corporation, Astellas Pharma Inc., Allele Biotechnology and Pharmaceuticals, Inc., NuVasive, Inc., Mesoblast Ltd., Anterogen.Co., Ltd.,JCR Pharmaceuticals Co., Ltd. and AlloSource.

Key Developments:

In July 2022, CORESTEM (South Korea) continued enrolling participants for the Phase 3 clinical trial of NeuroNata-R. This therapy has received conditional approval for treating ALS patients in South Korea.

Products Covered:

  • Human Embryonic Stem Cells (HESCs)
  • Very Small Embryonic Like Stem Cells
  • Adult Stem Cells (ASCs)
  • Induced Pluripotent Stem Cells (iPSCs)

Therapy Types Covered:

  • Allogenic
  • Autologous

Technologies Covered:

  • Expansion and Sub-Culture
  • Cell Production
  • Cryopreservation
  • Cell Acquisition

Applications Covered:

  • Drug Discovery and Development
  • Regenerative Medicine

End Users Covered:

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Cell Banks

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Stem Cell Therapy Market, By Product

  • 5.1 Introduction
  • 5.2 Human Embryonic Stem Cells (HESCs)
  • 5.3 Very Small Embryonic Like Stem Cells
  • 5.4 Adult Stem Cells (ASCs)
    • 5.4.1 Epithelial/Skin
    • 5.4.2 Hematopoietic
    • 5.4.3 Neural
    • 5.4.4 Mesenchymal
    • 5.4.5 Other Adult Stem Cells (ASCs)
  • 5.5 Induced Pluripotent Stem Cells (iPSCs)

6 Global Stem Cell Therapy Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Allogenic
  • 6.3 Autologous

7 Global Stem Cell Therapy Market, By Technology

  • 7.1 Introduction
  • 7.2 Expansion and Sub-Culture
  • 7.3 Cell Production
    • 7.3.1 Cell Culture
    • 7.3.2 In-vitro Fertilization
    • 7.3.3 Isolation
    • 7.3.4 Therapeutic Cloning
  • 7.4 Cryopreservation
  • 7.5 Cell Acquisition
    • 7.5.1 Apheresis
    • 7.5.2 Bone Marrow Harvest
    • 7.5.3 Umbilical Blood Cord

8 Global Stem Cell Therapy Market, By Application

  • 8.1 Introduction
  • 8.2 Drug Discovery and Development

Regenerative Medicine

    • 8.3.1 Diabetes
    • 8.3.2 Incontinence
    • 8.3.3 Oncology
    • 8.3.4 Cardiovascular and Myocardial Infraction
    • 8.3.5 Neurology
    • 8.3.6 Injuries
    • 8.3.7 Orthopedics
    • 8.3.8 Liver Disorder
    • 8.3.9 Hematology
    • 8.3.10 Other Regenerative Medicines

9 Global Stem Cell Therapy Market, By End User

  • 9.1 Introduction
  • 9.2 Academic & Research Institutes
  • 9.3 Pharmaceutical & Biotechnology Companies
  • 9.4 Hospitals & Cell Banks

10 Global Stem Cell Therapy Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 CORESTEM
  • 12.2 Regrow Biosciences Pvt Ltd.
  • 12.3 Takeda Pharmaceutical Company Limited
  • 12.4 MEDIPOST Co., Ltd.
  • 12.5 Orthofix Holdings, Inc.
  • 12.6 Smith & Nephew plc
  • 12.7 Novadip Biosciences
  • 12.8 Fujifilm Holding Corporation
  • 12.9 Astellas Pharma Inc.
  • 12.10 Allele Biotechnology and Pharmaceuticals, Inc.
  • 12.11 NuVasive, Inc.
  • 12.12 Mesoblast Ltd.
  • 12.13 Anterogen.Co., Ltd.
  • 12.14 JCR Pharmaceuticals Co., Ltd.
  • 12.15 AlloSource

List of Tables

  • Table 1 Global Stem Cell Therapy Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Stem Cell Therapy Market Outlook, By Product (2020-2028) ($MN)
  • Table 3 Global Stem Cell Therapy Market Outlook, By Human Embryonic Stem Cells (HESCs) (2020-2028) ($MN)
  • Table 4 Global Stem Cell Therapy Market Outlook, By Very Small Embryonic Like Stem Cells (2020-2028) ($MN)
  • Table 5 Global Stem Cell Therapy Market Outlook, By Adult Stem Cells (ASCs) (2020-2028) ($MN)
  • Table 6 Global Stem Cell Therapy Market Outlook, By Epithelial/Skin (2020-2028) ($MN)
  • Table 7 Global Stem Cell Therapy Market Outlook, By Hematopoietic (2020-2028) ($MN)
  • Table 8 Global Stem Cell Therapy Market Outlook, By Neural (2020-2028) ($MN)
  • Table 9 Global Stem Cell Therapy Market Outlook, By Mesenchymal (2020-2028) ($MN)
  • Table 10 Global Stem Cell Therapy Market Outlook, By Other Adult Stem Cells (ASCs) (2020-2028) ($MN)
  • Table 11 Global Stem Cell Therapy Market Outlook, By Induced Pluripotent Stem Cells (iPSCs) (2020-2028) ($MN)
  • Table 12 Global Stem Cell Therapy Market Outlook, By Therapy Type (2020-2028) ($MN)
  • Table 13 Global Stem Cell Therapy Market Outlook, By Allogenic (2020-2028) ($MN)
  • Table 14 Global Stem Cell Therapy Market Outlook, By Autologous (2020-2028) ($MN)
  • Table 15 Global Stem Cell Therapy Market Outlook, By Technology (2020-2028) ($MN)
  • Table 16 Global Stem Cell Therapy Market Outlook, By Expansion and Sub-Culture (2020-2028) ($MN)
  • Table 17 Global Stem Cell Therapy Market Outlook, By Cell Production (2020-2028) ($MN)
  • Table 18 Global Stem Cell Therapy Market Outlook, By Cell Culture (2020-2028) ($MN)
  • Table 19 Global Stem Cell Therapy Market Outlook, By In-vitro Fertilization (2020-2028) ($MN)
  • Table 20 Global Stem Cell Therapy Market Outlook, By Isolation (2020-2028) ($MN)
  • Table 21 Global Stem Cell Therapy Market Outlook, By Therapeutic Cloning (2020-2028) ($MN)
  • Table 22 Global Stem Cell Therapy Market Outlook, By Cryopreservation (2020-2028) ($MN)
  • Table 23 Global Stem Cell Therapy Market Outlook, By Cell Acquisition (2020-2028) ($MN)
  • Table 24 Global Stem Cell Therapy Market Outlook, By Apheresis (2020-2028) ($MN)
  • Table 25 Global Stem Cell Therapy Market Outlook, By Bone Marrow Harvest (2020-2028) ($MN)
  • Table 26 Global Stem Cell Therapy Market Outlook, By Umbilical Blood Cord (2020-2028) ($MN)
  • Table 27 Global Stem Cell Therapy Market Outlook, By Application (2020-2028) ($MN)
  • Table 28 Global Stem Cell Therapy Market Outlook, By Drug Discovery and Development (2020-2028) ($MN)
  • Table 29 Global Stem Cell Therapy Market Outlook, By Regenerative Medicine (2020-2028) ($MN)
  • Table 30 Global Stem Cell Therapy Market Outlook, By Diabetes (2020-2028) ($MN)
  • Table 31 Global Stem Cell Therapy Market Outlook, By Incontinence (2020-2028) ($MN)
  • Table 32 Global Stem Cell Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 33 Global Stem Cell Therapy Market Outlook, By Cardiovascular and Myocardial Infraction (2020-2028) ($MN)
  • Table 34 Global Stem Cell Therapy Market Outlook, By Neurology (2020-2028) ($MN)
  • Table 35 Global Stem Cell Therapy Market Outlook, By Injuries (2020-2028) ($MN)
  • Table 36 Global Stem Cell Therapy Market Outlook, By Orthopedics (2020-2028) ($MN)
  • Table 37 Global Stem Cell Therapy Market Outlook, By Liver Disorder (2020-2028) ($MN)
  • Table 38 Global Stem Cell Therapy Market Outlook, By Hematology (2020-2028) ($MN)
  • Table 39 Global Stem Cell Therapy Market Outlook, By Other Regenerative Medicines (2020-2028) ($MN)
  • Table 40 Global Stem Cell Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 41 Global Stem Cell Therapy Market Outlook, By Academic & Research Institutes (2020-2028) ($MN)
  • Table 42 Global Stem Cell Therapy Market Outlook, By Pharmaceutical & Biotechnology Companies (2020-2028) ($MN)
  • Table 43 Global Stem Cell Therapy Market Outlook, By Hospitals & Cell Banks (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.